RZLT Rezolute Inc
Company Analysis
Latest News
🟢 Rezolute is trading 5.6% up in after-hours trading despite no identified catalyst
Rezolute is trading at $4.88, up 5.63% after an unexplained after-hours rebound following its August 28 regular-session decline. - Shares fell 7.23% during...
🔴 Rezolute is trading 5% down today amid biotech-sector selloff
Rezolute is trading 5% down at $4.73 after a broad biotech-sector selloff; XBI fell 2.31% during regular trading. - The decline appears sector-driven....
🟢 Rezolute is trading 7.14% up in pre-market after Nvidia beat estimates and raised outlook
Rezolute is trading 7.14% up in pre-market at $5.40, mainly amid broader risk-on sentiment after Nvidia beat quarterly estimates and raised its outlook. - No...
🟢 Rezolute is trading 7.78% up in pre-market amid broader overnight risk-on sentiment
Rezolute is trading 7.78% up in pre-market at $5.40, apparently linked to broader overnight risk-on sentiment rather than a confirmed company-specific...
🟢 Rezolute is trading 5.59% up in pre-market amid broader risk-on sentiment
Rezolute is trading at $5.29, up 5.59%, possibly supported by broader risk-on sentiment. - Nasdaq futures are up 0.65%, and technology shares are...
🟢 Rezolute is trading 13% up today
Rezolute is trading 12.66% up at $5.25, but no clear company-specific catalyst was identified for August 21, 2026. - The latest identifiable material update...
🟢 Rezolute is trading 9.98% up today — catalyst remains unclear
Rezolute is trading 9.98% up at $5.12, but no clear company-specific catalyst was identified for August 21, 2026. - The latest identifiable update remains...
🟢 Rezolute is trading 5.9% up today following positive FDA feedback on its Phase III program
Rezolute is trading 5.9% up at $5.20 following productive FDA Type B meeting outcomes for its Phase III ersodetug program in congenital hyperinsulinism. • The...
🔴 Rezolute is trading 6.45% down today amid broader biotech sector weakness
Rezolute is trading at $4.57 (-6.45%) amid a sharp intraday selloff, appearing to track broader biotech sector weakness rather than company-specific news. •...
🔴 Rezolute is trading 5.6% down today with no clear company-specific catalyst
Rezolute is trading at $4.71 (-5.61%) in pre-market following a weaker close on July 24, with no fresh company-specific catalysts identified. • The move...
🔴 Rezolute is trading 5.3% down today with no clear company-specific catalyst
Rezolute is trading 5.3% down at $5.03 today with no fresh company-specific catalysts, likely reflecting positioning after a strong move earlier in the...
🟢 Rezolute is trading 5% up today with no clear company-specific catalyst
Rezolute is trading 5% up today at $5.25 despite a lack of fresh company-specific headlines or fundamental catalysts. • No major news, FDA decisions, earnings...
🟢 Rezolute is trading 10.1% up
Rezolute is trading at $4.90, up 10.1% from a comparison close of $4.45 during regular trading. This is a price-action follow-up, so a separate catalyst may...
🟢 Rezolute Inc is trading 6.40% up
RZLT is trading at $4.74, up 6.40%.
Rezolute Downgraded to Strong Sell, Following Volatility in Metabolic Pipeline
Zacks Research downgraded Rezolute Inc. from hold to strong sell on Saturday, July 18. This rating cut signals strong bearish sentiment for the clinical-stage...
🟢 Rezolute is trading 5.4% up today on technical rebound after Phase 3 trial selloff
Rezolute is trading 5.4% up today at $4.61 as investors cautiously buy following an extreme selloff tied to the failed Phase 3 sunRIZE trial for ersodetug in...
🔴 Rezolute is trading 5.4% down today on continued fallout from Phase 3 trial failure
Rezolute is trading at $4.48 (down 5.4%) as investors continue to digest the failed Phase 3 sunRIZE trial for ersodetug in congenital hyperinsulinism. • The...
🔴 Rezolute Inc is trading 6.44% down in pre-market
RZLT is trading at $4.65, down 6.44% in pre-market.
🔴 RZLT is trading 5% down today extending weakness after Phase 3 trial failure
RZLT is trading at $4.93 (5% down) today, extending its recent decline as negative sentiment persists following the failed Phase 3 trial of its hypoglycemia...
🟢 RZLT is trading 5% up today after positive pipeline updates
RZLT is trading 5% up at $5.14 after recent positive updates on its hyperinsulinism programs. • On June 2, the company reported positive interim data from its...